ライフサイエンスコーパス: proliferator

1 demonstrate that the nonclassical peroxisome proliferator 4-phenyl butyric acid is an efficient induc

2 ypothesis that variability in the Peroxisome Proliferator Activated Receptor (PPAR) pathway would be

3 ne-S-transferase 4-4 (Gsta4(-/-))/peroxisome proliferator activated receptor alpha (Ppara(-/-)) doubl

4 lement binding protein 1 (CREB1), peroxisome proliferator activated receptor alpha (PPARA), and CCAAT

5 andbeta-oxidation byatRA requires peroxisome proliferator activated receptor delta.

6 The nuclear receptor peroxisome proliferator activated receptor gamma (PPARgamma) is a b

7 n vivo requires activation of the peroxisome proliferator activated receptor gamma (PPARgamma) pathwa

8 rionic gonadotropin (hCGbeta) and peroxisome proliferator activated receptor gamma (PPARgamma) were m

9 o acids (BCAA), and regulation of peroxisome proliferator activated receptor gamma (PPARgamma).

10 ate the nuclear hormone receptor, peroxisome proliferator activated receptor gamma (PPARgamma).

11 nd without lipid loading based on peroxisome proliferator activated receptor gamma coactivator 1alpha

12 Peroxisome proliferator activated receptor gamma coactivator 1alpha

13 Peroxisome proliferator activated receptor gamma coactivator 1alpha

14 , mitochondrial KATP channels and peroxisome proliferator activated receptor gamma coactivator-1 (PGC

15 Peroxisome proliferator activated receptor gamma, coactivator 1alph

16 on bodyweight loss, induction of peroxisome proliferator activated receptor-alpha (PPARalpha)-regula

17 The peroxisome proliferator activated receptor-alpha (PPARalpha)/retino

18 erations in pathways regulated by peroxisome proliferator activated receptor-gamma (PPARgamma).

19 Peroxisome proliferator activated receptor-gamma coactivator-1alpha

20 A series of new peroxisome proliferator activated receptors (PPARs) chiral ligands

21 receptor potential channels, and peroxisome proliferator activated receptors are also engaged by som

22 ds for cannabinoid and alpha-type peroxisome proliferator-activated (PPAR-alpha) receptors; (2) shift

23 Peroxisome proliferator-activated gamma coactivator 1-alpha (PGC1al

24 ere competitive ligands for human peroxisome proliferator-activated nuclear receptor gamma (PPARgamma

25 Agonism of human peroxisome proliferator-activated nuclear receptor gamma (PPARgamma

26 receptor (PXR) [rifampicin], and peroxisome proliferator-activated receptor (PPAR) alpha [4-chloro-6

27 and is upregulated by agonists of peroxisome proliferator-activated receptor (PPAR) alpha and gamma T

28 activation of the lipid regulator peroxisome proliferator-activated receptor (PPAR) alpha.

29 -FA were blocked by inhibitors of peroxisome proliferator-activated receptor (PPAR) beta/delta (ST247

30 We investigated the role of peroxisome proliferator-activated receptor (PPAR) beta/delta defici

31 ther the nuclear hormone receptor peroxisome proliferator-activated receptor (PPAR) beta/delta, a reg

32 The peroxisome proliferator-activated receptor (PPAR) family comprises

33 Consistent with previous studies, peroxisome proliferator-activated receptor (PPAR) gamma agonism rev

34 vealed that ZFP407 regulates many peroxisome proliferator-activated receptor (PPAR) gamma target gene

35 e adipocytic transcription factor peroxisome proliferator-activated receptor (PPAR) gamma, which regu

36 tivated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR), respectively, th

37 e report that CD8(+) TILs enhance peroxisome proliferator-activated receptor (PPAR)-alpha signaling a

38 potential vanilloid (TRPV)-1 and peroxisome proliferator-activated receptor (PPAR)-alpha.

39 Peroxisome proliferator-activated receptor (PPAR)-delta, a lipid nu

40 Peroxisome proliferator-activated receptor (PPAR)-gamma activation

41 ost of target proteins, including peroxisome proliferator-activated receptor (PPAR)-gamma coactivator

42 Studies on peroxisome proliferator-activated receptor (PPAR)-gamma ligands hav

43 (+30% Oil Red O stain [ORO], +50% peroxisome proliferator-activated receptor (PPAR)-gamma protein; P

44 arget of rapamycin (mTOR) and the peroxisome proliferator-activated receptor (PPAR)-gamma proteins.

45 is transcriptionally regulated by peroxisome proliferator-activated receptor (PPAR)alpha and under no

46 as a highly selective inhibitory peroxisome proliferator-activated receptor (PPAR)beta/delta ligand.

47 Peroxisome proliferator-activated receptor (PPAR)gamma activation,

48 cts with the transcription factor peroxisome proliferator-activated receptor (PPAR)gamma.

49 -laden adipocytes by upregulating peroxisome proliferator-activated receptor (PPARgamma) and CCAAT/en

50 ively advantageous allele for the peroxisome proliferator-activated receptor A (PPARA) gene, which wa

51 ug classes, risk was highest with peroxisome proliferator-activated receptor agonists (RR 1.42, 95% C

52 the Gpat4(-/-) BAT expression of peroxisome proliferator-activated receptor alpha (PPAR) target gene

53 re we show that activation of the peroxisome proliferator-activated receptor alpha (PPAR-alpha) by th

54 pe 1 (CB1) or type 2 (CB2) or via peroxisome proliferator-activated receptor alpha (PPAR-alpha) stimu

55 by controlling the expression of peroxisome proliferator-activated receptor alpha (Ppara), and treat

56 izes the ligand-binding domain of peroxisome proliferator-activated receptor alpha (PPARalpha) and in

57 ion and synergy between CREBH and peroxisome proliferator-activated receptor alpha (PPARalpha) in act

58 vity of the androgen-induced gene peroxisome proliferator-activated receptor alpha (PPARalpha) in mal

59 Peroxisome proliferator-activated receptor alpha (PPARalpha) is a m

60 Peroxisome proliferator-activated receptor alpha (PPARalpha) is a t

61 (PFOA) increases mouse and human peroxisome proliferator-activated receptor alpha (PPARalpha) subtyp

62 ockdown reduced the expression of peroxisome proliferator-activated receptor alpha (PPARalpha) target

63 her Astragaloside IV can activate peroxisome proliferator-activated receptor alpha (PPARalpha) to sti

64 CREBH interacts with peroxisome proliferator-activated receptor alpha (PPARalpha) to syn

65 Because peroxisome proliferator-activated receptor alpha (PPARalpha) transc

66 at overlaps binding sequences for peroxisome proliferator-activated receptor alpha (PPARalpha), carbo

67 afibrate, known activators of the peroxisome proliferator-activated receptor alpha (PPARalpha), induc

68 ells with Wy14,643, an agonist of peroxisome proliferator-activated receptor alpha (PPARalpha), rapid

69 (ROS) activate ligand binding to peroxisome proliferator-activated receptor alpha (PPARalpha), sugge

70 tes serine 73 (Ser(P)(73)) of the peroxisome proliferator-activated receptor alpha (PPARalpha), which

71 One of these NRs is peroxisome proliferator-activated receptor alpha (PPARalpha), which

72 The role of peroxisome proliferator-activated receptor alpha (PPARalpha)-mediat

73 drug and a potent agonist of the peroxisome proliferator-activated receptor alpha (PPARalpha).

74 ysis unraveled that inhibition of peroxisome proliferator-activated receptor alpha activity resulting

75 ith the hepatic nuclear receptors peroxisome proliferator-activated receptor alpha and liver X recept

76 ved, and we provide evidence that peroxisome proliferator-activated receptor alpha is constitutively

77 AMP-activated protein kinase and peroxisome proliferator-activated receptor alpha responsive gene th

78 -fold), whereas the expression of peroxisome proliferator-activated receptor alpha target genes was s

79 Peroxisome proliferator-activated receptor alpha target proteins we

80 f the nuclear receptor PPARalpha (peroxisome proliferator-activated receptor alpha) in both mouse and

81 Peroxisome proliferator-activated receptor alpha, a transcriptional

82 g protein-hepatocyte specific and peroxisome proliferator-activated receptor alpha, which are transcr

83 A striking increase in nuclear peroxisome proliferator-activated receptor alpha, which plays a dom

84 ta deletion or inhibition, as was peroxisome proliferator-activated receptor alpha.

85 metabolism and are targets of the peroxisome proliferator-activated receptor and liver X receptor tra

86 Nuclear receptor co-activator peroxisome proliferator-activated receptor co-activator 1 alpha (PG

87 alterations to downregulation of peroxisome proliferator-activated receptor coactivator 1alpha, the

88 We found that peroxisome proliferator-activated receptor delta (PPAR-delta) inter

89 istically, a HFD induces a robust peroxisome proliferator-activated receptor delta (PPAR-delta) signa

90 Peroxisome proliferator-activated receptor delta (PPARdelta) is a l

91 Peroxisome proliferator-activated receptor delta (PPARdelta) regula

92 ation of the transcription factor peroxisome proliferator-activated receptor delta (PPARdelta).

93 As from higher lipolysis activate peroxisome proliferator-activated receptor delta to induce FA oxida

94 ation, in the lung mesenchyme, of peroxisome proliferator-activated receptor gamma (master switch of

95 ly diminished ability to activate peroxisome proliferator-activated receptor gamma (MSDC-0602) would

96 d interactions between polar bear peroxisome proliferator-activated receptor gamma (pbPPARG) and sele

97 een OmpA and Ecgp96 downregulates peroxisome proliferator-activated receptor gamma (PPAR-gamma) and g

98 -6 transcript levels, and induced peroxisome proliferator-activated receptor gamma (PPAR-gamma) expre

99 Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a

100 xpression of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-gamma), whic

101 the intracellular butyrate sensor peroxisome proliferator-activated receptor gamma (PPAR-gamma).

102 al of its target genes, including peroxisome proliferator-activated receptor gamma (PPARG) and mannos

103 On the contrary, peroxysome proliferator-activated receptor Gamma (PPARG) expression

104 en-null background, we identified peroxisome proliferator-activated receptor gamma (Pparg), encoding

105 ression of a key adipogenic gene, peroxisome proliferator-activated receptor gamma (Pparg), to induce

106 (NP) platforms to deliver either Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) activa

107 Long-term exposure to peroxisome proliferator-activated receptor gamma (PPARgamma) agonis

108 We have recently shown that peroxisome proliferator-activated receptor gamma (PPARgamma) agonis

109 Peroxisome proliferator-activated receptor gamma (PPARgamma) and ru

110 phage differentiation by cleaving peroxisome proliferator-activated receptor gamma (PPARgamma) at Asp

111 Here, we have shown that the peroxisome proliferator-activated receptor gamma (PPARgamma) coacti

112 f TNF and IL-12 but low levels of peroxisome proliferator-activated receptor gamma (PPARgamma) during

113 siglitazone and pioglitazone, are peroxisome proliferator-activated receptor gamma (PPARgamma) full a

114 ce with a conditional deletion of peroxisome proliferator-activated receptor gamma (PPARgamma) in CD1

115 beta, C/EBPdelta, KLF5, KLF9, and peroxisome proliferator-activated receptor gamma (PPARgamma) in the

116 Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma) is a c

117 The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) is a k

118 Peroxisome proliferator-activated receptor gamma (PPARgamma) is a m

119 Peroxisome proliferator-activated receptor gamma (PPARgamma) is a n

120 ontrast, the master adipogenic TF peroxisome proliferator-activated receptor gamma (PPARgamma) is ess

121 The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) is the

122 A class of small molecules-peroxisome proliferator-activated receptor gamma (PPARgamma) ligand

123 Peroxisome proliferator-activated receptor gamma (PPARgamma) ligand

124 cellular matrix, particularly the peroxisome proliferator-activated receptor gamma (Ppargamma) pathwa

125 et formation and the induction of peroxisome proliferator-activated receptor gamma (PPARgamma) target

126 ruited to the promoter of Nox1, a peroxisome proliferator-activated receptor gamma (PPARgamma) target

127 Peroxisome proliferator-activated receptor gamma (PPARgamma) transa

128 ng protein alpha (C/EBPalpha) and peroxisome proliferator-activated receptor gamma (PPARgamma)) and l

129 Peroxisome proliferator-activated receptor gamma (PPARgamma), a mas

130 ct action on the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma), but t

131 Peroxisome proliferator-activated receptor gamma (PPARgamma), PPARg

132 ere a regulatory circuit in which peroxisome proliferator-activated receptor gamma (PPARgamma), the a

133 ding protein H (CREBH) but not by peroxisome proliferator-activated receptor gamma (PPARgamma), which

134 pression is directly regulated by peroxisome proliferator-activated receptor gamma (PPARgamma), whose

135 is defect is because of defective peroxisome proliferator-activated receptor gamma (PPARgamma)-depend

136 n of the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARgamma).

137 s on interactions between Sp1 and peroxisome proliferator-activated receptor gamma (PPARgamma).

138 inding behavior of the adipogenic peroxisome proliferator-activated receptor gamma (PPARgamma):retino

139 concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARgamma, encode

140 The expression of placental peroxisome proliferator-activated receptor gamma (r = -0.39, P = 0.

141 ment by suppressing expression of peroxisome proliferator-activated receptor gamma 2 and lipid-drople

142 nflammatory response dependent on peroxisome proliferator-activated receptor gamma activity.

143 kinase inhibitor SP600125 and the peroxisome proliferator-activated receptor gamma agonist rosiglitaz

144 landin J2-dependent activation of peroxisome proliferator-activated receptor gamma and macrophage act

145 n 2 expression and suppression of peroxisome proliferator-activated receptor gamma and p27 expression

146 unication between the miR-130/301-peroxisome proliferator-activated receptor gamma axis in endothelia

147 g uncoupling protein 1 (Ucp1) and peroxisome proliferator-activated receptor gamma co-activator 1alph

148 The co-activator, peroxisome proliferator-activated receptor gamma co-activator 1alph

149 Erk5 regulation of peroxisome proliferator-activated receptor gamma co-activator-1alph

150 es uncoupling protein (UCP)-1 and peroxisome proliferator-activated receptor gamma coactivator (PGC)-

151 caused by a rapid degradation of Peroxisome proliferator-activated receptor gamma Coactivator (PGC-1

152 he expression of four isoforms of peroxisome proliferator-activated receptor gamma coactivator 1 alph

153 tance-associated protein 2 and 4, peroxisome proliferator-activated receptor gamma coactivator 1-alph

154 uanosine monophosphate (cGMP) and peroxisome proliferator-activated receptor gamma coactivator 1-alph

155 pothesized that overexpression of peroxisome proliferator-activated receptor gamma coactivator 1-alph

156 poptosis that was associated with peroxisome proliferator-activated receptor gamma coactivator 1-alph

157 tivated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-alph

158 e demonstrate, unexpectedly, that peroxisome proliferator-activated receptor gamma coactivator 1-alph

159 ursor) and its upstream activator peroxisome proliferator-activated receptor gamma coactivator 1-alph

160 Peroxisome proliferator-activated receptor gamma coactivator 1-alph

161 ependent of the activation of the peroxisome proliferator-activated receptor gamma coactivator 1-alph

162 Peroxisome proliferator-activated receptor gamma coactivator 1alpha

163 ranscription factor A (TFAM), and peroxisome proliferator-activated receptor gamma coactivator 1alpha

164 We show that peroxisome proliferator-activated receptor gamma coactivator 1alpha

165 ATP levels, reduced expression of peroxisome proliferator-activated receptor gamma coactivator 1alpha

166 decreased accumulation of active peroxisome proliferator-activated receptor gamma coactivator 1alpha

167 Peroxisome proliferator-activated receptor gamma coactivator 1alpha

168 Peroxisome proliferator-activated receptor gamma coactivator 1alpha

169 coexpression of the coactivators peroxisome proliferator-activated receptor gamma coactivator 1alpha

170 demonstrate that the coactivator peroxisome proliferator-activated receptor gamma coactivator 1alpha

171 mitochondrial DNA copy number and peroxisome proliferator-activated receptor gamma coactivator 1alpha

172 UCP1(+) cells also expressed the peroxisome proliferator-activated receptor gamma coactivator 1alpha

173 The transcriptional regulator peroxisome proliferator-activated receptor gamma coactivator 1alpha

174 d the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1beta

175 the transcriptional coactivators peroxisome proliferator-activated receptor gamma coactivator 1beta

176 reast cancer cells, IGF-1 induces peroxisome proliferator-activated receptor gamma coactivator 1beta

177 Peroxisome proliferator-activated receptor gamma coactivator-1 alph

178 le of ERK1/2 on the expression of peroxisome proliferator-activated receptor gamma coactivator-1alpha

179 , FOXO3A, and FOXO4 and decreased peroxisome proliferator-activated receptor gamma coactivator-1alpha

180 through increased translation of peroxisome proliferator-activated receptor gamma coactivator-1alpha

181 ntially through the regulation of peroxisome proliferator-activated receptor gamma coactivator-1alpha

182 own to regulate and interact with peroxisome proliferator-activated receptor gamma coactivator-1alpha

183 3, a transcriptional regulator of peroxisome proliferator-activated receptor gamma expression that co

184 paired box gene 8 (PAX8) with the peroxisome proliferator-activated receptor gamma gene (PPARG), resu

185 d the transcriptional activity of peroxisome proliferator-activated receptor gamma in luciferase repo

186 deoxy Delta-prostaglandin J2, and peroxisome proliferator-activated receptor gamma in this response.

187 inally, application of a specific peroxisome proliferator-activated receptor gamma inhibitor abolishe

188 not dependent on the decrease in peroxisome proliferator-activated receptor gamma levels.

189 Unexpectedly, oxidized fatty acid peroxisome proliferator-activated receptor gamma ligands 13- and 9-

190 sibly through oxidized fatty acid peroxisome proliferator-activated receptor gamma ligands, and it ca

191 R-130/301-specific control of the peroxisome proliferator-activated receptor gamma regulates a panel

192 rminal kinase, thereby inhibiting peroxisome proliferator-activated receptor gamma through serine 84

193 ably, I148M cells display reduced peroxisome proliferator-activated receptor gamma transcriptional ac

194 hat phosphorylation of PPARgamma (peroxisome proliferator-activated receptor gamma) at serine 273 by

195 ine 273 phosphorylation of Pparg (peroxisome proliferator-activated receptor gamma).

196 STAT6, Kruppel-like factor 4, and peroxisome proliferator-activated receptor gamma, and can reduce cy

197 drial transcriptional coactivator peroxisome proliferator-activated receptor gamma, coactivator 1-alp

198 f the transcriptional coactivator peroxisome proliferator-activated receptor gamma-coactivator 1alpha

199 biogenesis regulator Pgc-1alpha (peroxisome proliferator-activated receptor gamma-coactivator 1alpha

200 crophage lipid metabolism through peroxisome proliferator-activated receptor gamma-dependent regulati

201 s in rats were reported to induce peroxisome proliferator-activated receptor gamma-dependent transgen

202 ht to be due to activation of the peroxisome proliferator-activated receptor gamma.

203 ce or in mice given inhibitors of peroxisome proliferator-activated receptor gamma.

204 differentiation was mediated via peroxisome proliferator-activated receptor gamma.

205 landin J2-dependent activation of peroxisome proliferator-activated receptor gamma.

206 nhibitors of cyclooxygenase 2 and peroxisome proliferator-activated receptor gamma.

207 es, and ameliorated activation of peroxisome proliferator-activated receptor gamma/sterol regulatory

208 ol the regulator of adipogenesis, peroxisome proliferator-activated receptor gamma2 (Ppargamma2).

209 ctin receptor agonists, selective peroxisome proliferator-activated receptor modulators, cellular glu

210 atory mediators and repression of peroxisome proliferator-activated receptor signaling and oxidative

211 pathways, some linked to altered peroxisome proliferator-activated receptor signaling, muscle contra

212 eek due to failure to undergo the peroxisome proliferator-activated receptor signaling-dependent swit

213 e epoxide hydrolase (sEH) and the peroxisome proliferator-activated receptor type gamma (PPARgamma).

214 Activation of the PPAR (peroxisome proliferator-activated receptor)-fatty acid oxidation pa

215 cid beta-oxidation with GW7647, a peroxisome proliferator-activated receptor-alpha (PPARalpha) activa

216 Peroxisome proliferator-activated receptor-alpha (PPARalpha) displa

217 d mTORC1 signaling was activated, peroxisome proliferator-activated receptor-alpha (PPARalpha) phosph

218 Elafibranor is an agonist of the peroxisome proliferator-activated receptor-alpha and peroxisome pro

219 to identify the mechanism whereby peroxisome proliferator-activated receptor-alpha confers a survival

220 Peroxisome proliferator-activated receptor-alpha expression in nonh

221 ival in sepsis than hematopoietic peroxisome proliferator-activated receptor-alpha expression.

222 ought to characterize the role of peroxisome proliferator-activated receptor-alpha in sepsis and to i

223 Peroxisome proliferator-activated receptor-alpha is significantly d

224 Peroxisome proliferator-activated receptor-alpha null (Ppara) mice

225 ild-type mice irrespective of the peroxisome proliferator-activated receptor-alpha status of the bone

226 nhr-49 (an ortholog of the human peroxisome proliferator-activated receptor-alpha), and a key regula

227 of the PLIN5 gene is regulated by peroxisome proliferator-activated receptor-alpha, fasting, and exer

228 er partners, liver X receptor and peroxisome proliferator-activated receptor-alpha, key inhibitors of

229 hese results suggest that altered peroxisome proliferator-activated receptor-alpha-mediated cellular

230 Because peroxisome proliferator-activated receptor-beta/delta (PPARbeta/del

231 To determine whether peroxisome proliferator-activated receptor-D (PPARD) could possibly

232 potent, selective agonist for the peroxisome proliferator-activated receptor-delta (PPAR-delta), whic

233 mone secretagogue ibutamoren, the peroxisome proliferator-activated receptor-delta agonist GW501516,

234 ator-activated receptor-alpha and peroxisome proliferator-activated receptor-delta.

235 ultures, 2) likewise blocked by a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agoni

236 d intake and altered signaling by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and s

237 Some nuclear receptors, including peroxisome proliferator-activated receptor-gamma (PPAR-gamma), may

238 ation of the transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-gamma), whic

239 iglitazone, a specific agonist of peroxisome proliferator-activated receptor-gamma (PPAR-gamma).

240 with NAFLD, hepatic expression of peroxisome proliferator-activated receptor-gamma (PPARG) coactivato

241 iption of ABCG1 and ABCA1 through peroxisome proliferator-activated receptor-gamma (PPARG)-responsive

242 ement of insulin resistance using peroxisome proliferator-activated receptor-gamma (PPARgamma) agonis

243 revealed that the mRNA levels of peroxisome proliferator-activated receptor-gamma (PPARgamma) and a

244 ions between prenatal DHA and the peroxisome proliferator-activated receptor-gamma (PPARgamma) genoty

245 Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a l

246 Peroxisome proliferator-activated receptor-gamma (PPARgamma) was do

247 s alpha and beta (LXRalpha,beta), peroxisome proliferator-activated receptor-gamma (PPARgamma), and a

248 anscription factors including the peroxisome proliferator-activated receptor-gamma (PPARgamma), and i

249 ent were associated with enhanced peroxisome proliferator-activated receptor-gamma (PPARgamma), insul

250 show that dietary SCFAs induce a peroxisome proliferator-activated receptor-gamma (PPARgamma)-depend

251 abetic drugs that are agonists of peroxisome proliferator-activated receptor-gamma (PPARgamma).

252 othyronine increased sirtuin-1, fibrillin-1, proliferator-activated receptor-gamma 1-alpha (PGC1alpha

253 Furthermore, we show that peroxisome proliferator-activated receptor-gamma agonists also atte

254 human (mini-)organ, and show that peroxisome proliferator-activated receptor-gamma agonists are promi

255 Peroxisome proliferator-activated receptor-gamma agonists attenuate

256 ven partially reversed ex vivo by peroxisome proliferator-activated receptor-gamma agonists, likely t

257 In addition, the up-regulated peroxisome proliferator-activated receptor-gamma and -alpha (PPAR-g

258 showed significant reductions in peroxisome proliferator-activated receptor-gamma and CD36 in those

259 nscription coactivator PGC-1beta (peroxisome proliferator-activated receptor-gamma co-activator-1beta

260 he master mitochondrial regulator peroxisome proliferator-activated receptor-gamma coactivator (PGC1a

261 eins, and herein we identify that peroxisome proliferator-activated receptor-gamma coactivator 1 (PGC

262 tochondrial biogenesis regulators peroxisome proliferator-activated receptor-gamma coactivator 1-alph

263 Peroxisome proliferator-activated receptor-gamma coactivator 1-alph

264 ceptor-gamma coactivator 1-alpha, peroxisome proliferator-activated receptor-gamma coactivator 1-beta

265 y the transcriptional coactivator peroxisome proliferator-activated receptor-gamma coactivator 1.

266 ased bile acid levels suppress expression of proliferator-activated receptor-gamma coactivator 1alpha

267 regulator of fatty acid metabolism, and that proliferator-activated receptor-gamma coactivator 1alpha

268 Decreased proliferator-activated receptor-gamma coactivator 1alpha

269 e and thyroid hormone mediate the peroxisome proliferator-activated receptor-gamma coactivator-1alpha

270 id hormone promotes expression of peroxisome proliferator-activated receptor-gamma coactivator-1alpha

271 Changes in the regulation of peroxisome proliferator-activated receptor-gamma coactivator-1alpha

272 5; myocyte enhancer factor 2, and peroxisome proliferator-activated receptor-gamma coactivator-1alpha

273 nes and a persistent reduction in peroxisome proliferator-activated receptor-gamma expression.

274 eraction between STAT1, p300, and peroxisome proliferator-activated receptor-gamma is required for 15

275 with cholesterol or activation of peroxisome proliferator-activated receptor-gamma with pioglitazone

276 nts of the liver clock, including peroxisome proliferator-activated receptor-gamma, coactivator 1 (Pg

277 ransferable factor able to induce peroxisome proliferator-activated receptor-gamma-mediated upregulat

278 ) released from the heart trigger peroxisome proliferator-activated receptor-gamma-mediated upregulat

279 rterial NADPH oxidase triggered a peroxisome proliferator-activated receptor-gamma-mediated upregulat

280 s SREBP-1 interference increased, peroxisome proliferator-activated receptor-stimulated expression of

281 three isoforms identified for the peroxisome proliferator-activated receptors (PPARs) and is the rece

282 Peroxisome proliferator-activated receptors (PPARs) are nuclear hor

283 Peroxisome proliferator-activated receptors (PPARs) regulate both i

284 Peroxisome proliferator-activated receptors (PPARs) regulate energy

285 fibrate (BEZ), a pan activator of peroxisome proliferator-activated receptors (PPARs), has been gener

286 eating metabolic diseases are the peroxisome proliferator-activated receptors (PPARs), PPAR-alpha, PP

287 is dependent on the activation of peroxisome proliferator-activated receptors (PPARs), we investigate

288 nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs).

289 one of the three isoforms of the Peroxisome Proliferator-Activated Receptors (PPARs).

290 are consistent with induction of peroxisome proliferator-activated receptors and disruptions of the

291 ia-inducible factor 1 (Hif-1) and peroxisome proliferator-activated receptors.

292 polysis to induce the activity of peroxisome proliferator-activated receptors.

293 , we investigate allostery in the peroxisome proliferator-activated/retinoid X receptor heterodimer.

294 sure led to pre-existing elevated peroxisome proliferators-activated receptor-gamma co-activator (PGC

295 autophagy, and the expression of peroxisome proliferator gamma coactivator 1 alpha (PGC-1alpha).

296 the liver X receptors (LXRs) and peroxisome-proliferator receptor gamma (PPARgamma).

297 aracterized role of 15d-PGJ2 as a peroxisome proliferator receptor-gamma agonist, its activation of N

298 ational analysis identified three peroxisome proliferator response elements (PPREs) within the 863-nt

299 Finally, in vitro high-proliferator status was statistically linked to diminish

300 The peroxisome proliferator, WY 14,643 exhibits a pure non-competitive